NCT06989489 Implementation of an Oral Chemotherapy Adherence Intervention
| NCT ID | NCT06989489 |
| Status | Recruiting |
| Phase | — |
| Sponsor | UNC Lineberger Comprehensive Cancer Center |
| Condition | Solid Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2025-05-28 |
| Primary Completion | 2028-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 160 participants in total. It began in 2025-05-28 with a primary completion date of 2028-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to evaluate the effectiveness and usability of a newly developed oral anticancer agent adherence program implemented across 6 cancer clinics (two academic, two urban, and two rural). The study will include 160 adult participants with either solid tumors or hematologic malignancies who have been taking oral anticancer agents for at least six months. This study will have two groups of participants, a pre- and post-implementation group. In the pre-implementation of the program group, investigators will administer a survey to the 80 participants and gather information about their medication prior to their enrollment of the program. Similarly, 80 participants who have been enrolled into this program for at least 6 months will serve as the post-implementation group. These patients will be administered the same survey. The results from both groups will be analyzed to see how effective the medication adherence program is.
Eligibility Criteria
Inclusion Criteria: * Adult (age ≥21 years-old) patients * Diagnosed with a solid or hematologic malignancy * Monotherapy on oral anticancer agent on treatment for at least 6 months Exclusion criteria: * Patients on time-limited or intermittent therapy (non-continuous) * Patients on comfort (end-of-life) care * Patients enrolled on hospice
Contact & Investigator
Benyam Muluneh, PharmD
PRINCIPAL INVESTIGATOR
UNC Lineberger Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT06989489 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Solid Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06989489 currently recruiting?
Yes, NCT06989489 is actively recruiting participants. Contact the research team at solsay@unc.edu for enrollment information.
Where is the NCT06989489 trial being conducted?
This trial is being conducted at Chapel Hill, United States.
Who is sponsoring the NCT06989489 clinical trial?
NCT06989489 is sponsored by UNC Lineberger Comprehensive Cancer Center. The principal investigator is Benyam Muluneh, PharmD at UNC Lineberger Comprehensive Cancer Center. The trial plans to enroll 160 participants.